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CHAPTER 1: INTRODUCTION
Myelin and the Central Nervous System
In 1543 Andreas Vesalius mapped the brain and therein described what he termed
then “white matter” and “grey matter” areas. Thus, began the study of myelin sheaths in
the central nervous system (Boullerne et al, 2016). In the nearly 500 years that have
followed, much progress has been made. Advancements in technology have allowed
scientists to make discoveries regarding myelin that Vesalius would have never thought
possible.
Early studies of myelin focused on elucidating the form and function of myelin
sheaths. It wasn’t until 1925 that Ralph Stayner Lillie suggested that myelin is necessary
for the rapid propagation of action potentials through the nervous system via saltatory
conduction and it was well after WWII that myelin’s function as an insulator was confirmed
(Boullerne et al, 2016).
The origin of myelin was not confirmed until the mid-1950’s, and the function of
oligodendrocytes was not found until 1962. This was 50 years after oligodendrocytes
were first described by Pio del Rio Hortega (Boullerne et al, 2016). Prior to this time, it
was believed that myelin was formed directly by axons. This discovery changed the face
of myelin research in the central nervous system (CNS) henceforth.
Myelination is a multistep process that begins with the generation and proliferation
of oligodendrocyte precursor cells (OPCs) (Snaidero and Simons, 2017). OPCs
differentiate from cells that originate in the ventricular zones in the brain. The
differentiation of OPCs into mature oligodendrocytes is a process that occurs over time
and involves genetic, biochemical, structural, and physiological changes within the cell.
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The expression of developmental markers allows OPCs to differentiate into
phenotypically different types of mature oligodendrocytes that have varying functions
throughout the white and grey matter of the CNS. There are 4 types of myelinating
oligodendrocytes (Butt et al, 1995) that can be identified through morphological
differences.
Oligodendrocyte’s primary purpose within the CNS is myelination of axons. Unlike
the myelinating cells of the peripheral nervous system (PNS), oligodendrocytes can
myelinate multiple axons at a time. Oligodendrocytes ensheath small and large diameter
axons in a multi-lamellar fashion, with the leading edge at the inner tongue around the
axon and moving outward. This process requires the production of a variety of proteins
that are needed at different times throughout the process for a variety of tasks (Snaidero
and Simons, 2017). Any disruption of the CNS myelin, either through injury, pathological
degeneration, or genetic intervention (Nave et al, 1994) leads to severe functional deficits
and disease.
Proteolipid Protein 1 and Pelizaeus-Merzbacher Disease
The Plp1 gene codes for Proteolipid Protein 1 (PLP) whose structure is preserved
across species. The gene is 17.4 kb long and is located on chromosome Xq22.3 (Boison
and Stoffel, 1994). PLP (276 amino acids) and its isoform DM20 (which lacks 35 amino
acids specific to PLP) are tetraspan membrane proteins whose expression are highly
regulated during brain development because they play a major role during the myelination
of the CNS (Readhead et al, 1994). PLP/DM20 are the most abundant proteins in CNS,
making up approximately 50% of the protein mass in the myelin. PLP is most highly
expressed by oligodendrocytes and seems to play a major role in the structural stability
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of myelin sheaths formed by these cells (Campagnoni and Skoff, 2001) by functioning in
spiral wrapping, membrane compaction, and the fine architecture of multilayered sheath
(Klugmann et al, 1997). However, these proteins are expressed elsewhere as well and
are known to function in the regulation of apoptosis throughout the body, especially during
development (Skoff, 2004). It is suspected that not all roles of PLP are known and
understood as this protein is complex pathogenically (Klugmann et al, 1997).
Pelizaeus-Merzbacher disease (PMD) results from proteolipid protein 1
(PLP1/Plp1) gene mutations. PMD is a rare, x-linked, hypomyelinating disease
characterized by delayed motor and cognitive development, nystagmus, ataxia,
hypotonia, and spasticity (Seitelberger et al, 1995; Garbern, 2007). PLP1/Plp1 mutations
fall into four categories: duplications, point mutations, deletions, and frameshift mutations
(Hüttemann et al, 2009) each of which affects the severity and onset of PMD. Therefore,
PMD has been divided into 2 subtypes (Nave and Boespflug-Tanguy, 1996): 1) The
connatal form, resulting primarily from PLP1 point mutations, is the most severe form of
PMD and usually leads to death within the first decade. 2) The classic form, which results
from PLP1 duplications, is the most common form (50-75% of cases) and onsets at
around two months of age. Those affected can live several decades with variable
neurological deficits (Koeppen et al, 2002).
The mildest form of PMD, often confused with spastic paraplegia type 2 as it is not
always possible to discriminate between them, results from PLP1 null mutations
(Garbern, 2007). This form of the disease can manifest during the teenage years, and
although the effected males present a much milder phenotype when compared to
patients/model animals with PLP1/Plp1 mutations or missense mutations, patients still
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have a shortened lifespan (Raskind et al, 1991; Inoue et al, 2002). PLP1/Plp1 null
mutations result in a lack of synthesis of PLP and although PLP constitutes 50% of myelin
protein, myelin still forms and is essentially normal (Klugmann et al, 1997). This results in
a clinically distinct disorder from the classic forms of PMD that is often ignored because
of it mild phenotype.
Because of differences resulting from the variety of PLP1/Plp1 mutations, care
should be taken not to generalize observations found in PLP1/Plp1 null cases with other
PMD subsets as pathogenic findings are unique to each mutation. Therefore, describing
the central pathologic differences between PLP1 mutation types in humans is worthy of
attention because it could lead to a more refined discussion on future therapies (Laukka
et al, 2016).
PLP and Inflammation: M1 vs M2
In many neurodegenerative diseases, microglial activation and an inflammatory
response have been described (i.e. Parkinson’s and Alzheimer’s). It is known that
changes in expression of myelin proteins, specifically PLP, are associated with
progressive massive microglial inflammation in animal models of PMD (Bachstetter et al,
2013; Tatar et al, 2010; Ip et al, 2006). Activation of the innate immune system,
particularly of astrocytes and microglia, is mostly associated with the deleterious role of
neuroinflammation and could contribute to neuronal death in PMD patients. Studies in
Plp1tg and jimpy mice have enabled the unmasking of a strong inflammatory environment
when PLP is duplicated (Plp1tg) or mutated (jimpy) characterized by extensive microglial
activation, up-regulation of pro-inflammatory cytokines (Tatar et al, 2010) and
involvement of T-cells in myelin degeneration (Ip et al, 2006). Years of study has brought
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to realization that neuroinflammation is not restricted to PMD animal models, but that it is
also likely a significant hallmark of PMD in humans (Skoff, unpublished data). Drs. Carrie
Tatar and Robert Skoff to studied inflammation specifically in the Plp1tg mice. They found
intense microglia reactivity and an up-regulation of many pro-inflammatory cytokines and
chemokines (Tatar et al, 2010). Causal links have been determined have been suggested
between insertion of PLP into mitochondria, metabolic abnormalities, changes in the
extracellular fluid, microglia activation, and neurodegeneration in Plp1tg mice (Appikalta
et al, 2013). The increased production of proinflammatory cytokines by microglia in these
mice, along with their typical amoeboid morphology implies a M1 (or classical)
inflammatory response in these animals.
M1 microglia are characterized by their amoeboid shape, high motility, strong
phagocytic capacity, and production and release of pro-inflammatory cytokines and
chemokines (Du et al, 2017). These cells are otherwise known as “classical” microglia
and have long been thought to be the primary type of activated microglia cell. These cells
are known for their ability to kill/fight (Rath et al, 2014). They are associated with TLRs,
NODs, and NOD like receptors that respond to TNF-α, IL-6, IL-1b, and INF-γ. They
produce ROS and NOS (specifically iNOS), both of which attribute to the death of
surrounding cells (Cherry et al, 2014). Because of this, iNOS is often used as a marker
specific to M1 microglia cells.
Microglial activation has classically been considered destructive, however, in many
disease states these cells are known defenders. Since the immune system functions to
protect the brain it is logical to propose that the primary function of microglia is protective
(Chen and Trapp, 2016). This leads us to the other end of the of the microglial spectrum:

6

M2 microglia cells. These cells are known for their healing/fixing properties (Rath et al,
2014). They can suppress neuroinflammation, restore homeostasis and help protect the
brain (Chen and Trapp, 2016). The classification of these cells is more complex as they
are any cells that show a response ”alternative” to the classic M1 response. This variation
in response is based of varying environmental clues. Often the production of antiinflammatory cytokines/chemokines such as IL-4, IL-13, and IL-10 is associated with an
M2 response (Cherry et al, 2015). M2 cells are generally characterized by thin cell bodies
and branched processes (often referred to as transitional morphology) (Du et al, 2017).
Arg1 is commonly used as a marker for these cells. Both Arg1 and iNOS originate from
arginine, thus Arg1 is a iNOS competitor that pushes microglia towards the M2 phenotype
(Cherry et al, 2014).
Unlike that found in the Plp1tg mice, Plp1ko mice seems to adopt a more
beneficial, anti-inflammatory (likely M2) phenotype, that could explain the benefits of Plp1
deletion vs Plp1 duplication.
Hypothesis and Aim of Research
Aim of Research: Investigate how abnormal expression of PLP in
oligodendrocytes directly or indirectly leads to activation of an inflammatory
response and, in turn, cell death in mouse models. This study focused on
measurement of the inflammatory response in Plp1tg, wtPlp1, and Plp1ko mice. I
quantified overall microglial cell number, cell morphology, and branching. Cells were
further characterized through measurement of cytokines and chemokines at mRNA and
protein levels to determine whether they had a destructive (M1) or protective (M2) function
in the CNS of Plp1ko mice.
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Previous studies have shown that PLP is inserted into the mitochondria of
oligodendrocytes of Plp1tg and wtPlp1 mice (Hüttemann et al, 2004). The mechanisms
through which PLP is inserted into oligodendrocyte mitochondria via the Mia40/Tom40Erv1 pathway is understood. Based upon PLP’s co-localization with creatine kinase
(Hüttemann et al, 2004), it appears to be present in the inter-membrane space. PLP has
motifs (CX3C and CX9C) in its N-terminus (C6, C10, C25, and C35) that match the
Mia40/Tom40-Erv1 relay system used to transport proteins into mitochondria. Mutation
of any of these cysteines blocks PLP from being inserted into the mitochondria of
oligodendrocytes (Hüttemann et al, 2004). When the Plp1 gene is duplicated, this
insertion results in metabolic defects: a decrease in mitochondria membrane potential
(Hüttemann et al, 2004) and acidification of media and extra cellular fluid through and
increase in ATP (Appikalta et al, 2014). These phenomena are quite different from the
commonly accepted view that PLP is exclusively a myelin adhesive protein and that the
pathology in the PLP mutants is due to demyelination and/or hypomyelination. It is likely
that wild type PLP plays an important role in mitochondrial function and that improper
titration leads to a diseased state in the form of microglial activation (Tatar et al, 2010).
Current data suggest PLP plays a role as a protein channel in mitochondria (Skoff,
unpublished data).
This activation, in turn, likely contributes to the extensive neuronal degeneration
described in humans and mice that have PLP1/Plp1 gene duplications. Plp1ko mice
experience less oligodendrocyte apoptosis than either wtPlp1 or Plp1tg mice (Skoff et al,
2004). I hypothesize that activated microglia in these Plp1ko mice may play an
alternative, protective, role.
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CHAPTER 2: THE INFLAMMATORY RESPONSE IN Plp1KO MICE VS Plp1TG MICE
EXPERIMENTAL DESIGN AND METHODS
Animals
Two transgenic mouse colonies, kindly provided by Dr. Klaus Nave, were used for
this study. One with a duplication the Plp1 gene exhibiting at least a twofold transcriptional
over-expression of Plp1 (Plp1tg line #66) (Readhead et al, 1994) and another in which
the Plp1 gene is not expressed (Plp1ko) (Klugmann et al, 1997). Two control mouse
colonies, B6129 for Plp1ko and C57BL/6 for Plp1tg (Jackson Laboratory, Bar Harbor, ME,
U.S.A.), were used as well. Male and female Plp1ko mice and B6129 controls were used
at 1, 3, and 6 months of age. Plp1tg mice and C57BL/6 controls were used at 1 month of
age as the lifespan of the Plp1tg mice is less than three months.
All mice were obtained from our breeding colonies (where the lines have been
maintained for 15 years) housed in the Division of Laboratory Animal Resources (DLAR)
at Wayne State School of Medicine (Detroit, MI), a federally approved animal facility. All
mice were housed in DLAR animal facilities that are under the direct supervision of the
Institutional Animal Care and Use Committee (IACUC), a federally approved institutional
committee; all procedures were approved by the Wayne State University IACUC.
Genotyping
The genotypes of Plp1tg and Plp1ko mice were identified by extraction of DNA
from tail clips with the Extract-n-Amp kit (Sigma-Aldrich, St. Louis, MO, U.S.A.) between
14 and 21 days. DNA from mice was used to measure expression of the Plp1 gene.
Quantitative PCR was performed with an Eppendorf PCR system using PCR mix from kit
and two sets of primers: PLP3F: 5’-ACGAGCAGTGAGAGTTGGGT-3’ and PLP4R:5’-
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AGTCTGTTTTGCGGCTGACT-3’ and NEO4:5’-GGCTATTCGGCTATGACTGGGC-3’
and NEO5:5’-GGGTAGCCAACGCTATGTCCTGA-3’ to amplify PLP and the neo
cassette. Only the neo band is amplified in homozygous Plp1ko mice in males and
females. PCR products were resolved on a 1.5% agarose gel and visualized with ethidium
bromide.
Iba1 Immunocytochemistry
All rodents used for immunocytochemistry (ICC) were anesthetized with an
intraperitoneal lethal dose of chloral hydrate (650 mg/kg body weight) in accordance with
Wayne State University IACUC protocols and perfused intracardially with 4% (w/v)
paraformaldehyde (PFA) in phosphate-buffered saline (PBS). Whole brains were
removed, placed in PFA, and stored at 4°C until further use. Fifty μm transverse sections
were cut coronally with a Vibratome, placed in PBS as free-floating sections, and
processed for Iba1. Sections were rinsed and mounted on glass slides. Controls for all
ICC consisted of sections where the primary antibody was eliminated.
Fifty μm sections from 1, 3, and 6 months old B6129 and Plp1ko male and female
mice and 1 month C57BL/6 and Plp1tg mice were washed with PBS, treated with 3%
H2O2 for 30 min, washed with PBS, incubated in sodium citrate buffer (10 mM sodium
citrate, 0.1% tween) pH 6 for 30 min at 80° C and 30 minutes at room temperature,
washed with PBS, treated with 10% Triton-X for 30 min, washed with PBS, blocked with
10% (v/v) goat serum for 30 minutes, washed with PBS, and incubated in polyclonal antiIba1 (ionized calcium-binding adaptor molecule 1) antibody (Wako, Richmond, VA,
U.S.A.) diluted 1:500 overnight in 0.1 M PBS at room temperature (20° C). Sections were
rinsed in PBS and incubated in goat anti-rabbit IgG horseradish peroxidase (HRP;
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Jackson ImmunoResearch, West Grove, PA, U.S.A.) conjugated antibody diluted 1:100
and detected using 0.5 mg/ml DAB (diaminobenzidine) (Sigma–Aldrich, St. Louis, MO,
U.S.A.). Immunofluorescence was also done using the same protocol exchanging the
HRP secondary antibody for goat anti-rabbit ALEXA 594 (Jackson ImmunoResearch,
West Grove, PA, U.S.A.)
Three to 6 animals were used for each time point, sex, and strain. For each animal,
3 to 4 matched transverse sections were blindly counted for Iba1 labeled cells using a
Leitz (Wetzlar, Germany) Laborlux microscope equipped with a ×50 oil objective and a
×10
Cortex
Corpus Callosum

Figure 1: Quantification of Iba1
ICC. Iba1 quantification was
completed in 2 areas of the brain.
A white matter area in the corpus
callosum just lateral the ventricle,
and a grey matter area in the
cortex adjacent to the dorsal interhemispheric fissure on one side.
All cells within a 10x10 mm grid
were counted.

eyepiece

containing a 1cm2

grid

divided into 1
mm
Cells

squares.
were

counted in the

corpus callosum just lateral the ventricle and adjacent to the dorsal inter-hemispheric
fissure (Figure 1). The number of cells for each area was summed; averages were
determined for each animal and then for each strain. Values represent mean ± SEM of 3
to 4 sections per animals. Data significance was determined using an ANOVA assuming
equal variance. This analysis has been completed previously in Plp1tg mice (Tatar et al,
2010).
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BrdU/Iba1 Immunocytochemistry
For combined Iba1 and BrdU (bromodeoxyuridine) ICC of wtPlp1 and Plp1ko mice,
mice were injected with 100 μg of BrdU/g of body weight intraperitoneally and perfused
with 4% paraformaldehyde 70 hours later. This length of interval from injection to sacrifice
permits microglia/microglial precursors to divide and differentiate. Brains were removed
and 50 μm sections cut coronally using a Vibrotome. Sections were washed in PBS,
treated with 2 M HCl for 30 minutes at 37° C, incubated in 0.1 M sodium borate 2x for 30
minutes at room temperature, treated with 3% H2O2, incubated in PBS-blocking buffer
(PBS containing 0.2% BSA, 0.2% milk and 1.0% Triton) for 30 minutes and incubated
with anti-BrdU (BD Biosciences, San Jose, CA, U.S.A.) diluted 1:100 at 4° C overnight.
Sections were rinsed in PBS, incubated in an anti-mouse HRP (Jackson
ImmunoResearch)
conjugated antibody and
developed

with

DAB+cobalt. Sections were

Corpus Callosum and
External Capsule

then rinsed in PBS and
processed

for

Iba1

immunocytochemistry

Figure 2: Quantification
of BrdU expressing
microglial
cells.
Microglial cells double
labeled with Iba1 and
BrdU
were
counted
through an oil immersion
lens throughout the entire
half of the corpus
callosum and external
capsule.

using DAB (without cobalt)
as previously described. This work has been completed previously in Plp1tg mice (Tatar
et al, 2010).
Quantification was completed as described for Iba1 with only a slight variation.
Cells were counted in one entire side of corpus callosum and external capsule (as in
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Cerghet et al, 2006; Figure 2). The number of cells for each area was summed and
averages determined for each animal and then for each strain. Values represent mean ±
SEM of 3 to 4 sections per animal. Data significance was determined using an ANOVA
assuming equal variance.
Quantification of Microglial Activation
Using sections treated with Iba1 (as above), microglial activation was quantified
based on number of microglial processes and the complexity of branching (Karperien et
al, 2013.) Cells with more than 4 processes were counted as ramified (inactive) cells,
those with 2-4 processes were counted as transitional cells, and those with less than 2
Ramified

processes were counted as amoeboid
(Figure 3). “Transitional” describes any cell

Transitional

Transitional

that is between the ramified stage and the
amoeboid stage. At each time point (1, 3,
and 6 months), sex, and strain (wtPlp1,
Plp1ko and Plp1tg), 3 to 6 animals were

Amoeboid

used. For each animal, 3 to 4 matched

Figure 3: Various
stages of microglial
(Activated)
activation based on branching
patterns. Activated cells have fewer
branches than inactive cells. Taken from
Karperien 2013.

transverse sections branching patterns of
Iba1 labeled cells adjacent the dorsal interhemispheric fissure were analyzed using a

Leitz microscope as described above.
Percentage of activated microglial cells in Plp1ko and wtPlp1 male and female
mice was verified through double CD68 (activated microglial cell marker) and Iba1 double
labelling ICC. 50 μm sections were washed in PBS, treated with 3% H2O2, washed with
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PBS, incubated in 0.1 M sodium citrate (pH 6) for 15 minutes at 80° C and 15 minutes at
room temperature, washed with PBS, and incubated in anti-CD68 (Proteintech,
Rosemont, IL, U.S.A.) diluted 1:200 in PBS overnight at room temperature. Sections were
washed in PBS, incubated in anti-rabbit HRP (Jackson ImmunoResearch) conjugated
antibody and developed with DAB+cobalt. Sections were then treated for Iba1 ICC.
Percentage of activated microglia was quantified by counting cells showing CD68/Iba1
colocalization (black and brown staining) as well as all Iba1 labelled cells and determining
the percentage of Iba1+ cells also expressing CD68 in the corpus callosum near the
ventricle and near the dorsal inter-hemispheric fissure.
Cytokine ELISA
Six 6-month old male Plp1ko and wtPlp1 mice were quickly perfused by
transcardial perfusion with cold PBS to remove blood. Brains were removed on ice and
placed in sterile tubes. They were then immersed in liquid nitrogen to “snap freeze” and
stored at -80° C for later use. One half of each brain was used for the ELISA. Brains were
homogenized by addition of 1-3 ml protein extraction buffer (20 Mm Tris-HCL pH 7.5, 150
mM Na2EDTA, 1 Mm EGTA, 1 % Triton-X, proteinase inhibitor cocktail added freshly, and
phosphatase inhibitor cocktail added freshly) and an electric homogenizer. This was done
on ice. Brains of both Plp1ko and wtPlp1 mice were homogenized under the same
conditions. Homogenates were vortexed and kept on ice for 30 minutes before being
centrifuged to remove tissue debris for 20 minutes at 13,000 rpm at 4° C. Supernatants
were aliquoted and saved at -80° C. Protein levels were determined by BCA and adjusted
to make sure that all samples were the same.
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ELISA was run using an inflammatory cytokines multianalyte ELISA from QIAGEN
that measures the concentrations of 10 common inflammatory cytokines: IL-1a, IL-1b, IL2, IL-4, IL-6, IL-10, IL-12, IL-17a, IFN-y, TNF-a, GCSF, and GM-CSF. Samples from 3
Plp1ko and 3 wtPlp1 were run on each plate following the kit protocol. These were
compared to samples from Plp1tg mice and controls. Data were analyzed, and data
significance was determined using an ANOVA by group assuming equal variance.
Arg1/iNOS Western Blot
Three-month-old male Plp1ko, Plp1tg, and wtPlp1 (B6129 and C57BL/6) mice
were quickly perfused by transcardial perfusion with cold PBS to remove blood. Brains
were removed on ice and placed in sterile tubes. They were then immersed in liquid
nitrogen to “snap freeze” and stored at -80° C for later use.
Brains were homogenized by addition of 1-3 ml protein extraction buffer (see
above) and an electric homogenizer. This was done on ice. All mice were homogenized
under the same conditions. Homogenates were vortexed and kept on ice for 30 minutes
before being centrifuged to remove tissue debris for 20 minutes at 13,000 rpm at 4° C.
Supernatants were aliquoted and saved at -80° C. Protein levels were determined by BCA
and adjusted to make sure that all samples were the same.
Western blots were probed with markers for arginase 1 (Protein Tech), iNOS
(Protein Tech) and β-actin (Sigma). A standard 4–12% gel was used. Each gel was
transferred on to a PVDF membrane, membranes were blocked with 5% (w/v) non-fat
powdered milk, incubated in antibody (1:500) overnight in 1% milk, washed with PBS-T,
incubated with secondary antibody (1: 10,000) for 1 hour in 1% milk, washed in PBS-T
and detected using the ChemiLucent Detection System (Chemicon). Arginase 1 and
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iNOS densities were determined using ImageJ software (NIH) and adjusted to β-actin for
consistency. Data were analyzed, and significance was determined using a 2-tailed
Student’s t-test comparisons assuming unequal variance.
Arg1/iNOS Immunocytochemistry
Fifty μm sections from 1, 3, and 6 months old B6129 and Plp1ko male and female
mice and 1 month C57BL/6 and Plp1tg mice were washed with PBS, treated with 3%
H2O2 for 30 min, washed with PBS, incubated in sodium citrate buffer (10 mM sodium
citrate, 0.1% Tween) pH 6 for 20 min at 80° C and 40 minutes at room temperature,
washed with PBS, and incubated in polyclonal anti-Arg1 or anti-iNOS antibody
(Proteintech, Rosemont, IL, U.S.A.) diluted 1:50 overnight in 0.1 M PBS at room
temperature (20° C). Sections were rinsed in PBS and incubated in goat anti-rabbit IgG
horseradish peroxidase (HRP; Jackson ImmunoResearch, West Grove, PA, U.S.A.)
conjugated antibody diluted 1:100 and detected using 0.5 mg/ml DAB (diaminobenzidine)
(Sigma–Aldrich, St. Louis, MO, U.S.A.). Immunofluorescence was also done using the
same protocol exchanging the HRP secondary antibody for goat anti-rabbit ALEXA 594
(Jackson ImmunoResearch, West Grove, PA, U.S.A.)
Arg1/iNOS rtPCR and Quantification of mRNA
The transcardial perfusion of Plp1ko, B6126, Plp1tg, and C57BL/6 mice under
anesthesia was performed with pre-cold PBS to remove brain blood. Mouse brain was
quickly dissected and kept at -80°C. Half of mouse brain was homogenized in 2 mL of
TRIZOL Reagent using a glass-Teflon homogenizer. Following homogenization, insoluble
material was removed from the homogenate by centrifugation at 12,000 x g for 10 minutes
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at 4° C. Cleared homogenate solution was to a fresh tube. Total RNA purification
proceeded following the instruction of TRIZOL® Reagent (Life Technologies).
The iScript™ cDNA Synthesis Kit (Bio-Rad) was used for cDNA synthesis. Each
reaction volume included 4 ul of 5x iScript reaction buffer, 1 ul of iScript reverse
transcriptase, 1 µg total RNA and nuclease-free water up to 20 ul. Complete reaction mix
was incubated 5 minutes at 25°C, 30 minutes at 42°C, 5 minutes at 85°C and held at 4°
C. cDNA reaction mix was diluted in 200 ul nuclease-free water.
Eppendorf Realplex 2.0 rtPCR system and Power SYBR® Green PCR Master Mix
(Thermofisher) were used to perform real-time PCR. Each real-time PCR reaction
included

3

ul

cDNA

dilution

(above),

2

ul

primers

(iNOS

F:

GTTCTCAGCCCAACAATACAAGA, iNOS R: GTGGACGGGTCGATGTCAC, Arg1 F:
CTCCAAGCCAAAGTCCTTAGAG, Arg1 R: AGGAGCTGCATTAGGGACATC), 5 ul
nuclease-free water, and 10 ul Power SYBR Green PCR Master Mix. Reaction mix
underwent thermal-cycling as described: 10 minutes at 95°C for Enzyme Activation,
denature in 15 seconds at 95°C, and 60 seconds at 60°C for 40 cycles. The 2-ΔΔCT
Method was used for data analysis. Data significance was determined using an ANOVA
assuming equal variance.
ATP Measurements in Plp1ko and wtPlp1 Mice
The measurement of ATP in brain was done using a previously published
procedure for measuring pH in brain (Skoff et al., 2004). Plp1ko and wtPlp1 mice at 1, 3,
and 6 months were sacrificed by cervical dislocation, brains removed and 2-2.5mm
sections from the cortex and the corpus callosum were dissected using a razor blade,
weighed, and cut into 16 cubes and placed in a vial on ice containing 1ml ice-cold artificial
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cerebral spinal fluid (aCSF) (124mM NaCl, 3mM KCl, 3mM CaCl2, 1.5mM MgCl2, 26mM
NaHCO3, 1mM NaH2PO4, 10mM D-glucose, and 75μM HEPES) and a magnetic stir bar.
Fluid and tissue were gently stirred on a magnetic stir plate for 5 min. Afterwards the
contents of the vials were transferred to 1.5ml centrifuge tubes and centrifuged for 1 min.
Brain tissue and aCSF was separated and immediately frozen in liquid nitrogen and ATP
measured by a member of Maik Hüttemann’s lab. ATP of each sample was measured in
triplicate, averaged, and then averaged for each group of brains. Data was analyzed using
an ANOVA by groups to test for significance.
RESULTS
Increased number of microglia in Plp1ko mice
Iba1 is a polyclonal antibody that recognizes an ionized calcium-binding adaptor
molecule that is only expressed in microglia in the brain (Imai et al, 1996; Graeber et al,
1998; Ito et al, 1998). This antibody has been used to identify microglia in many
mammalian species (Tonchev et al, 2003; Yamada et al, 2006). Plp1ko mice have
significantly more (2-3 fold) Iba1+ microglial cells (indicative of an inflammatory response
occurring) in both white and grey matter (Figure 1) of the cerebrum at all time points
compared with B6129 control mice (P<0.05; Figures 4 and 5). The results indicate that
the density of microglial cells is higher in Plp1ko mice; increase in density is consistent
throughout cerebrum (P>.05, Figure 7). It is likely that the increase in microglia in Plp1ko
mice is even greater than the cell counts indicate because microglia are clustered
together making it difficult to determine the exact number of cells.
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Figure 4: Number of microglia (based on
Iba1 ICC) in wtPlp1 (B6129) and Plp1ko at
1, 3, and 6 months of age in the corpus
callosum. Plp1ko mice have an increased
number of microglial cells at all time points
when compared to wtPlp1 mice. Data from
males and females combined. N=6. P<.01.
ANOVA. * Compares wtPlp1 to Plp1ko at the
same time points (colors match).
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Figure 6: Number of microglia in male and
female mice at 3 months compared in
corpus callosum. No significant difference in
number of microglial cells between males and
females in wtPlp1 (B6129) and Plp1ko mice at
any time point. N=3. P>.05. ANOVA.
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Figure 5: Number of microglia (based on
Iba1 ICC) in wtPlp1 (B6129) and Plp1ko at
1, 3, and 6 months of age near the dorsal
inter-hemispheric fissure. Plp1ko mice have
an increased number of microglial cells at all
time points when compared to wtPlp1 mice.
Data from males and females combined. N=6.
P<.01. ANOVA. * Compares wtPlp1 to Plp1ko
at the same time points (colors match).
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Figure 7: Number of microglia in white
matter and grey area compared at 3
months. Comparable areas. No significant
difference in number of microglial cells in
either wtPlp1 (B6129) or Plp1ko mice at any
time point. N=3. P>.05. ANOVA. Same
pattern found at 1 and 6 months.
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Studies have shown sexual dimorphism exists among glial cells (Cerghet et al,
2009), however in this study, we found no significant difference in number of microglia
between males and females in either the wtPlp1 or the Plp1ko mice (P>.05; Figure 6).
This insignificance is verified by an ANOVA and is true at all time points: 1, 3, and 6
months.
Increased microglia proliferation in Plp1ko mice
Inflammation causes an increase in the proliferation of microglial cells. BrdU is
incorporated into cells during the DNA synthesis phase of the cell cycle and can be used
Figure 8: Iba1/BrdU
ICC in a Plp1ko
mouse.
Iba1
was
developed with DAB
(brown) while BrdU was
developed
with
DAB+cobalt (black).

to quantify number of proliferating
cells throughout the brain. Data
from this study shows that in
addition to microglial activation
being

increased

in

Plp1ko,

microglia are also stimulated to divide. Combined Iba1 and BrdU ICC was performed on
wtPlp1 and Plp1ko cerebra (Figure 8). Figure 8 also shows many BrdU+ cells that are not
Iba1+; these cells serve as a control to show that the BrdU-labelled cells are not nonspecifically labelled with the Iba1 antibody.
All BrdU+/Iba1+ cells within half of the corpus callosum and external capsule were
counted (see Methods and Materials). Plp1ko mice have significantly more proliferating
microglia cells than wtPlp1 (3-fold increase) at all time points and in both sexes (Figures
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9 and 10). This helps to explain the significant increase in overall microglial cell number
in Plp1ko mice when compared to wtPlp1 mice (p<.05, Figure 9).

BrdU+/Iba1+ Cells in Male vs
Female Mice

15
10

*

5
0
wtPlp1
1 Month

3 Months

Plp1ko
6 Months

Figure 9: BrdU quantification in
wtPlp1 (B6129) and Plp1ko mice at
ages 1, 3, and 6 months in corpus
callosum. Plp1ko mice have an
increased number of proliferating
microglial cells at all time points when
compared to wtPlp1 mice. Data from
males and females combined. N=6.
ANOVA. P<.05. * Compares wtPlp1 to
Plp1ko (colors match).

# BrdU+/Iba1+ Cells

BrdU+/Iba1+ Cells

BrdU+/Iba1+ Cells in Mice
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Figure 10: Number of BrdU+ microglia
in male and female mice at three
months in corpus callosum. No
significant difference in number of
microglial cells in wtPlp1 (B6129) and
Plp1ko mice at any time point. N=3.
ANOVA. P>.05. Compares like colors.
Same pattern found at 1 and 6 months
(data not shown).

Microglial activation quantified by number of processes and complexity of
branching
Activated microglia change shape as their cell bodies enlarge and become more
amoeboid. Cells lose processes and the remaining processes have far fewer branches
than those of ramified cells (Figure 3). In this study, activation of Iba1+ cells was classified
by number of processes and branching complexity (see Methods).
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Branching Patterns of Microglial Cells in Male Mice

% Total
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Figure 11: Quantification of microglial activation based on number of processes
and complexity of branching patterns at 1, 3, and 6-month old male mice in the
cortex near the dorsal inter-hemispheric fissure. Cell activation was quantified based
on number of processes branching directly from cell body. 4+ processes=ramified cell,
2-4 processes=transitional cell, and <2 processes=amoeboid. wtPlp1 mice show mostly
ramified cells, while Plp1ko mice show mostly primed/reactive cells. Similar data found
in females (data not shown) N=3. ANOVA. P<.01 for all groups.

Branching Patterns of Microglia
in 1 Month Old Male Mice

CD68+ (Activated) Microglia in
Cortex of Mice
% Total Microglia

% Total
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12:
Quantification
of
Figure
microglial activation in wtPlp1
(B6129 and C57Bl/6), Plp1ko, and
Plp1tg mice at one month. Plp1tg
mice have more amoeboid cells than
the Plp1ko mice. N=3. ANOVA. *P<.01.

Plp1ko
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Plp1tg
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Figure 13: Quantification of CD68+
microglial cells near the dorsal interhemispheric fissure in wtPlp1 (B6129
and C57Bl/6) and Plp1ko mice at 1, 3,
and 6 months and Plp1tg at 1 month.
Number of activated microglial cells
increases from wtPlp1 to Plp1ko to
Plp1tg. N=6. ANOVA. *P<.01.
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Data suggest that wtPlp1 mice have more ramified microglia than transitional or
amoeboid microglia. In contrast, Plp1ko mice have a high number of transitional cells
compared to ramified or amoeboid microglia (see Figure 11). Both wtPlp1 and Plp1ko
mice have relatively few amoeboid cells, especially when compared to Plp1tg mice
(Figure 12). These differences were found to be significant using an ANOVA and a p<.01.
These patterns are the same at all time points (1, 3, and 6 months; Figure 11). Analysis
was done only in grey matter as in white matter processes extend along the tracts, making
it difficult to determine the number of branches.
CD68 ICC was used to verify the percentage of activated microglia cells in Plp1ko,
Plp1tg and wtPlp1 mice. This protein is localized to the lysosomal membrane in microglia
and is up-regulated in actively phagocytic cells. Both M1 polarized and M2 polarized
microglia can express CD68 (Walker and Lue, 2005.) Numbers were consistent with
those found through branching analysis with wtPlp1 showing 20-40%, Plp1ko showing
60-75%, and Plp1tg mice showing around 80% activated microglia cells (Figure 13). Data
was found to be significant.
Microglial morphology of Plp1ko mice compared to wtPlp1 and Plp1tg mice
Iba1 immunostained microglial cells are present throughout the grey and white
matter of both the normal B6129 and the Plp1ko mouse. Typical microglia in normal
cerebra, often referred to as ramified, have characteristic long and thin processes (Figure
3). Their primary processes are usually twice the length of the axis of the cell body.
Secondary processes branch acutely from primary processes, and sometimes tertiary
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processes are distinguishable (Tatar et al, 2010). The ramified morphology is similar at
all ages in normal B6129 mice (Figure 14).
The morphology and dispersion of microglial cells in the cortical, striatal, and
callosal regions of the cerebra in the Plp1tg mice differ drastically from that of control mice
(Figure 14). Activated microglia in Plp1tg are distinguished by coarse short processes
and an enlargement of the cell body. Amoeboid microglia have far fewer processes than
ramified cells. Microglia are often clustered together and brush-like processes become
wtPlp1

Plp1tg

Plp1ko

Figure 14: Iba1 ICC of microglia in Plp1tg, wtPlp1, and Plp1ko mice. Cells in Plp1tg and Plp1ko
mice are activated in appearance when compared to wtPlp1 mice. Plp1tg mice act as control
examples of activated microglia.
entangled (Tatar et al, 2010).
The morphology and dispersion of microglia cells throughout the brain of the
Plp1ko mice most closely matches that found in the Plp1tg mice (Figure 14). Microglia
are clustered together like the cells in the Plp1tg mice, but to a lesser degree. Fewer
amoeboid microglia are found in Plp1ko mice compared to Plp1tg mice (Figure 12 and
14). More cells are found to be in the transitional stage with more processes and
branches. It is likely that inflammation in Plp1ko mice is less severe than in Plp1tg mice.
Plp1ko Mice Show Decrease in Expression of Pro-Inflammatory Cytokines
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Over activation of M1 microglial cells and excessive amounts of proinflammatory
cytokines have been shown to result in neurodegenerative consequences in various
diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and multiple sclerosis (Du,
2016). Some examples of proinflammatory cytokines are: IL-1α, IL-1β, IL-6, IL-12, IL-17α,
IFN-γ, and TNF-α.
These cytokines are produced or stimulated by M1 (or classical) microglia. Several
of these have been shown to be increased in the Plp1tg mice (Tatar, 2010). This, along
with the massive increase in oligodendrocyte cell death, implies a M1 microglial response
in the Plp1tg mice. However, the Plp1ko mice show either a decrease in the cytokines or
no change (see Figure 15) implying an M2 (or alternative) response in these animals.
Cytokine levels were measured using a ELISA assay (see methods).

Cytokine Expression
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Figure 15: ELISA assay shows decrease in many pro-inflammatory cytokines in
Plp1ko mice. Compared to wtPlp1 mice, Plp1ko mice show decreased expression of many
pro-inflammatory cytokines, such as: IL-1a, IL-1b, IL-12, IL-17a, and TNFa. Decrease in proinflammatory cytokine expression implies an alternative phenotype of activated microglia in
Plp1ko mice. N=5. T-Test, 2 tails. P>.05. Significance indicated by * (orange vs blue).
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Microglia in Plp1ko Mice Show Alternative (M2) Phenotype Compared to Plp1tg
Mice
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wtPlp1 Mice
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Figure 17. mRNA and protein levels of
M1/M2 microglia markers in Plp1ko
mice. These mice show a decrease in
iNOS (M1) and a decrease in Arg1 (M2)
implying a something other than a classical
inflammatory response. N=4. P values
shown in figure. 2 tailed T-Test.

Protein

Figure 16. mRNA and protein levels of
M1/M2 microglia markers in Plp1tg
mice. These mice show an increase in
iNOS (M1) and a decrease in Arg1 (M2)
implying
a
classical
inflammatory
response. N=4. P values shown in figure. 2
tailed T-Test.
Data led me to believe that Plp1ko mice are not experiencing a classical M1
microglia response, but, instead, are experiencing an alternative response. mRNA and
Western blot analysis for iNOS (M1 marker) and Arg1 (M2) marker verified this
hypothesis. This data is only preliminary and experiments need to be repeated to increase
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statistical significance. I need to consider that microglia aren’t the only cells that produce
cytokines. Astrocytes do as well.
As expected of a classical M1 inflammatory response, microglia in Plp1tg mice
show an increase in protein levels of iNOS and decreased levels of Arg1 (Figure 16).
Plp1ko mice show something different (see Figure 17), implying an M2, or alternative
response. This helps to explain the benefits of a lack of PLP when compared to mice and
humans that overexpress PLP.
ATP Measurements in Plp1ko’s Do Not Indicate Mitochondrial Dysfunction
Inflammation in Plp1tg mice has been linked to mitochondrial dysfunction in the
form of increased extracellular ATP (Tatar, et al, 2010). Measurements of extracellular
ATP in Plp1ko mice do not show the same results (Figure 18). There is no difference
found in levels of extracellular ATP found between Plp1ko and wtPlp1 mice. This is likely
because PLP plays a role as a protein channel in oligodendrocyte mitochondria and
increasing the amount of
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Figure
18.
Extracellular
ATP
levels
NOT
increased in Plp1ko
mice. 1, 3, and 6month mice. N=6.
ANOVA. No significant
difference found.
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DISCUSSION AND CONCLUSIONS
Male PMD patients with null mutations often do not exhibit motor and sensory
symptoms until their 20's and they survive into their 50's (Raskind et al., 1991; Garbern
et al., 1997; Inoue et al., 2002). Similarly, PLP deficient mice lack behavioral signs in their
first year and have a nearly normal life span (Boison and Stoffel 1994; Klugmann et al.,
1997). The myelin in these animals is essentially normal (Klugmann et al., 1997.) Thus,
animals with a null mutation of the PLP1/Plp1 gene have better outcomes compared to
animals with extra copies or missense mutations of the wtPLP1/Plp1 gene. These
findings, along with the data showing that cellular abnormalities in PLP1/Plp1 mutations
are not limited to oligodendrocytes but include astrocytes, microglia (Tatar et al., 2010)
and neurons, indicate that PLP plays an important role outside the myelin.
While the principal function of PLP is often considered to be that of an adhesive
molecule in myelin (Boison et al., 1995), numerous studies show that PLP and DM20
have other functions (Nadon and West, 1998; Campagnoni and Skoff, 2001) including
regulation of cell death (Skoff et al., 2004) and protein channel (Skoff, unpublished data).
Recently, major oxidative phosphorylation defects in the Plp1tg mice have been
described, specifically, a decrease in mitochondrial membrane potential and increase in
extracellular ATP. This likely stems from an increase in PLP protein channels in
mitochondria, though this has yet to be proven. Previous studies (Hüttemann et al., 2009;
Appikalta et al., 2014) have found that when the Plp1 gene is duplicated, PLP is inserted
into the mitochondria utilizing unpaired twin C X3C or CX9C motifs that are present in the
N-terminus of PLP. The metabolic defects due to the insertion of PLP into mitochondria
are quite different from the commonly accepted view that PLP is exclusively a myelin
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adhesive protein and that the pathology in the PLP mutants is due to demyelination and/or
hypomyelination and are likely due to PLP playing a role as a protein channel in
oligodendrocyte mitochondria (Skoff, unpublished data).
Major oxidative phosphorylation defects in neurons as well as oligodendrocytes
(Hüttemann et al., 2009) in Plp1tg mice seem to lead to dramatic morphological changes
of microglia, as well as an increase in expression of pro-inflammatory cytokines and
chemokines (Tatar et al., 2010). Activation of microglia by increases in extracellular or
exogenous ATP has been described in numerous studies (Gyoneva et al., 2009; Monif et
al., 2009; Puthussery and Fletcher, 2009). Only a slight increase of ATP is needed to
activate microglia. Exogenous ATP, in turn, activates microglial purinergic receptors
(Davalos et al., 2005).
Here I have described, for the first time, an inflammatory response in Plp1ko mice.
They, like Plp1tg mice, show intense microglial reactivity, thought to stem from
mitochondrial dysfunction, though current data indicate otherwise. Although it remains to
be determined whether and how the inflammation contributes to the neural degeneration
in the PMD model mice, the well-known role of cytokine and chemokine activation in other
neurodegenerative diseases makes it likely that microglial activation contributes to
disease progression in Plp1tg mice and human patients.
We find that deletion of the Plp1 gene leads to dramatic morphological changes of
microglia. Changes include the shortening and thickening of microglial processes as well
as an increased number, though not to the same extent as Plp1tg mice. The
morphological changes in Plp1ko mice are as dramatic in the grey matter as in the white
matter. This is like what was found in Plp1tg mice (Tatar et al., 2009). We found a
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doubling of microglia throughout the cerebra of the Plp1ko mice and, as noted, these
numbers are likely to be underestimated because microglia are densely clustered
together. Data suggest that microglial activation is caused by other factors/molecules
besides degeneration of myelin and is likely due to change in expression of PLP.
The intense microglial reactivity in Plp1ko mice suggested activation of multiple
cytokines and chemokines. This is, however, not congruent with the low levels of
oligodendrocyte cell death in Plp1ko mice (Skoff, et al, 2004). In Plp1tg mice mRNA
expression of classical inflammatory markers TNF-α and IL-6 were elevated 24- and 7fold respectively in 2-month-old animals. mRNA of nine other chemokines were elevated
by more than 3-fold and several were down-regulated. For some of these chemokines
such as CCL3/MIP-1a (macrophage inflammatory protein), its receptor (CCR1) is also
up-regulated (Tatar et al., 2009). It is interesting that this is not the case in Plp1ko mice.
Recall that pro-inflammatory cytokine/chemokine levels are either decreased or
unchanged in these mice. Studies examining the microglia determine that Plp1tg mice
have an M1 (cytotoxic) and Plp1ko mice have an M2 (neuroprotective) phenotype help to
explain this.
Further studies are necessary to elucidate the mechanisms that lead to
inflammation in the Plp1tg vs the Plp1ko mice, as well as downstream effects on neural
function and morbidity to truly understand why a Plp1ko genotype is beneficial over a
Plp1tg genotype for PMD patients.
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ABSTRACT
PROTEOLIPID PROTEIN 1 REGULATES INFLAMMATION IN THE CENTRAL
NERVOUS SYSTEM
by
WHITNEY HOFF
May 2018
Advisor: Dr. Robert Skoff
Major: Molecular Genetics and Genomics
Degree: Master of Science
Pelizaeus-Merzbacher disease (PMD) results from mutations in the proteolipid
protein 1 (PLP1) gene including PLP1 duplications and deletions. The absence of PLP is
preferable to PLP1/Plp1 duplication in PMD patients and rodents as lifespan of
PLP1/Plp1 null mammals is nearly normal. The reason for this is not entirely
understood. However, because of this, less attention has been placed on Plp1 null
mutations than on classical PMD mutations. However, data show that PLP levels must
be properly titrated to ensure normal brain function. Specifically, changes in PLP1/Plp1
expression can result in massive microglia activation in animal models of PMD and likely
in human PMD patients. We asked if PLP plays a role in this activation and how. We
hypothesized that PLP plays a necessary part in regulation of mitochondrial function and
that a disturbance in PLP expression leads to an inflammatory response because of this.
The purpose of this study was to investigate this hypothesis the Plp1ko mouse model as
it has been studied previously in animals with excess PLP (Plp1tg mice). We found an
extensive inflammatory response in Plp1ko as demonstrated by 2-3-fold increase in
both the overall microglial
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cell number in both male and female mice at 1, 3, and 6 months in Plp1ko mice. This
increase can be accounted for by a 3-fold increase in microglial proliferation throughout
the white and grey matter of the cerebra. Activity of microglia was quantified based on
branching patterns of cell processes and the expression of CD68 (a marker for activated
microglia). An increase in activation in Plp1ko mice is observable as early as 1 month and
continues to at least 6 months. Interestingly, morphology of microglia and the effects of
inflammation in Plp1ko mice differs from Plp1tg mice. A decrease in pro-inflammatory
cytokines, as well as an increase in arginase 1 expression in Plp1ko mice, leads us to
believe that while Plp1ko mice do experience an inflammatory response, microglia
reactivity could be neuroprotective due to an alternative, or M2, activation state. This antiinflammatory response would help to explain the benefits of Plp1 deletion vs Plp1
duplication. This study of Plp1ko mice, along with previous studies of Plp1tg mice,
uncovers a novel function of PLP: regulation of brain inflammation, most likely mediated
by the increase or absence of PLP in the mitochondria of oligodendrocytes. This must be
understood in greater detail if we are to understand therapies for PMD and other diseased
states.
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